Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Advances in the management of high-risk localised and metastatic prostate cancer.

Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W.

BJU Int. 2012 Mar;109 Suppl 2:8-13. doi: 10.1111/j.1464-410X.2011.10871.x.

2.

Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.

Bahl A, Bellmunt J, Oudard S.

BJU Int. 2012 Mar;109 Suppl 2:14-9. doi: 10.1111/j.1464-410X.2011.10872.x.

3.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
4.

[Therapeutic options and controversies in the management of prostate cancer].

Peyromaure M, Thiounn N.

Rev Prat. 2003 Dec 31;53(20):2263-7. French.

PMID:
15018081
6.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
7.

Locally advanced prostate cancer: effective treatments, but many adverse effects.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Review.

PMID:
23367679
8.

Maximizing outcomes in genitourinary cancers across the treatment continuum.

Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A.

BJU Int. 2011 Apr;107 Suppl 2:1-12. doi: 10.1111/j.1464-410X.2010.10035.x.

9.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.

10.

Metastatic castrate-resistant prostate cancer: dawn of a new age of management.

Masson S, Bahl A.

BJU Int. 2012 Oct;110(8):1110-4. doi: 10.1111/j.1464-410X.2012.11076.x. Epub 2012 May 7. Review.

11.

Current management of advanced and castration resistant prostate cancer.

Gomella LG, Petrylak DP, Shayegan B.

Can J Urol. 2014 Apr;21(2 Supp 1):1-6.

12.

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.

Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA.

J Urol. 2007 May;177(5):1777-81.

PMID:
17437819
13.

Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.

Bracarda S, Logothetis C, Sternberg CN, Oudard S.

BJU Int. 2011 Apr;107 Suppl 2:13-20. doi: 10.1111/j.1464-410X.2010.10036.x.

14.

Evolving treatment paradigms for locally advanced and metastatic prostate cancer.

Dorff TB, Quek ML, Daneshmand S, Pinski J.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1639-51. Review.

PMID:
17134367
15.

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.

Roach M 3rd.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):32-7; discussion 38. Review.

PMID:
8725889
16.

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.

MacVicar GR, Hussain MH.

Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161. Review.

PMID:
23511665
17.
18.

Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.

Lam ET, Glodé LM.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1189-204, viii. doi: 10.1016/j.hoc.2013.08.004. Epub 2013 Sep 21. Review.

PMID:
24188258
19.

Current controversies in the treatment of high-risk prostate cancer.

Mitchell RE, Chang SS.

Curr Opin Urol. 2008 May;18(3):263-8. doi: 10.1097/MOU.0b013e3282f9b37f. Review.

PMID:
18382235
20.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677

Supplemental Content

Support Center